Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epicatechin Extension in Becker Muscular Dystrophy
NCT03236662Phase 2Completed
- Start
- Nov 2016
- Primary completion
- Nov 2017
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of Catechin in Becker muscular dystrophy (BMD). Primary endpoints: Plasma Follistatin at 48 weeks, Plasma Myostatin at 48 weeks and 7 more. Started Nov 2016; status: completed.
02
Drugs
Catechin
03
Conditions
Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on NCT03236662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03236662.